Sonoma Pharmaceuticals, Inc. filed a supplement to its Prospectus Supplement to increase the aggregate offering price of common stock under its At Market Issuance Sales Agreement with Ladenburg Thalmann & Co. Inc. from the previous amount to $3,641,703. Since September 26, 2025, the company has sold 173,073 shares for a total of $574,633. Sonoma Pharmaceuticals, Inc. is a pharmaceutical company that develops and commercializes commercial products for the treatment of pain and pain-related disorders.